Accessibility Menu
Ocular Therapeutix Stock Quote

Ocular Therapeutix (NASDAQ: OCUL)

$11.77
(-3.4%)
-0.41
Price as of October 21, 2025, 4:00 p.m. ET

KEY DATA POINTS

Current Price
$11.77
Daily Change
(-3.4%) $0.41
Day's Range
$11.6 - $12.19
Previous Close
$11.77
Open
$12.18
Beta
1.51
Volume
1,853,659
Average Volume
2,693,466
Market Cap
2.6B
Market Cap / Employee
$12.18M
52wk Range
$5.79 - $13.85
Revenue
-
Gross Margin
0.89%
Dividend Yield
N/A
EPS
-$1.28
CAPs Rating
-
Industry
Pharmaceuticals

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Ocular Therapeutix Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
OCUL+3.52%+14%+2.65%-7%
S&P+15.06%+95.03%+14.29%+240%

Ocular Therapeutix Company Info

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$13.46M-18.1%
Gross Profit$11.52M-22.9%
Gross Margin85.56%-5.3%
Market Cap$1.48B39.5%
Market Cap / Employee$5.40M0.0%
Employees2742.6%
Net Income-$67.81M-54.9%
EBITDA-$66.61M-56.2%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$391.13M-14.9%
Accounts Receivable$30.41M0.6%
Inventory319.3%

Liabilities

Q2 2025YOY Change
Long Term Debt$74.31M1.5%
Short Term Debt$2.63M58.5%

Ratios

Q2 2025YOY Change
Return On Assets-44.76%-1.5%
Return On Invested Capital-59.60%21.7%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$56.48M-121.1%
Operating Free Cash Flow-$55.24M-122.7%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book3.583.803.675.56114.28%
Price to Sales23.6522.5220.8228.2752.26%
Price to Tangible Book Value3.583.803.675.56114.28%
Enterprise Value to EBITDA-24.44-22.54-15.38-19.339.95%
Return on Equity-96.9%-95.2%-57.2%-63.4%-12.74%
Total Debt$75.12M$75.78M$76.22M$76.94M2.74%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.